Related references
Note: Only part of the references are listed.Validation of the academic research consortium high bleeding risk criteria in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis of 10 studies and 67,862 patients
Angelo Silverio et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2022)
2021 ACC/AHA/SCAT Guideline for Coronary Artery Revascularization
Sripal Bangalore et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Validation of the ARC-HBR criteria in 68,874 patients undergoing PCI: A systematic review and meta-analysis
Claudio Montalto et al.
HELLENIC JOURNAL OF CARDIOLOGY (2022)
Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis
Toshiki Kuno et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2022)
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2021)
De-Escalation of DAPT After ACS Escalating the Odds of Getting It Right
Kwan S. Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention A Prespecified Subgroup Analysis of a Randomized Clinical Trial
J. J. Coughlan et al.
JAMA CARDIOLOGY (2021)
Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials
Eliano P. Navarese et al.
CIRCULATION (2020)
De-Escalation of Antiplatelet Treatment in Patients with Myocardial Infarction Who Underwent Percutaneous Coronary Intervention: A Review of the Current Literature
Daniel M. F. Claassens et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Ticagrelor or Prasugrel in Patients With ST-SegmentElevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Alp Aytekin et al.
CIRCULATION (2020)
Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Ahmad Al-Abdouh et al.
CARDIOVASCULAR REVASCULARIZATION MEDICINE (2020)
Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes
Christian Valina et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk
Philip Urban et al.
EUROPEAN HEART JOURNAL (2019)
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
Dirk Sibbing et al.
JACC-CARDIOVASCULAR INTERVENTIONS (2019)
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
Daniel M. F. Claassens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
S. Schuepke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PREVALENCE AND TIMING OF DE-ESCALATION THERAPY FROM TICAGRELOR TO CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS: RESULTS OF A META-ANALYSIS
Dominick Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
Elias J. Dayoub et al.
JAMA INTERNAL MEDICINE (2018)
Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database
Satoshi Yokoyama et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2018)
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study
Thomas Cuisset et al.
EUROPEAN HEART JOURNAL (2017)
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial
Dirk Sibbing et al.
LANCET (2017)
Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry
Leonardo De Luca et al.
EUROINTERVENTION (2017)
Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials
Pravesh Kumar Bundhun et al.
BMC PHARMACOLOGY & TOXICOLOGY (2017)
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome
Kibum Kim et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2017)
Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction A Secondary Analysis of the TRANSLATE-ACS Study
Patricia O. Guimaraes et al.
JAMA CARDIOLOGY (2017)
Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study
Marjorie E. Zettler et al.
AMERICAN HEART JOURNAL (2017)
International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies
Dominick J. Angiolillo et al.
CIRCULATION (2017)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
Glenn N. Levine et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Switching between thienopyridines in patients with acute myocardial infarction and quality of care
Francois Schiele et al.
OPEN HEART (2016)
In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study
Akshay Bagai et al.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2015)
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel - the European MULTIPRAC Registry
Peter Clemmensen et al.
EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE (2015)
No free lunches: balancing bleeding and efficacy with ticagrelor
James A. de Lemos et al.
EUROPEAN HEART JOURNAL (2011)
An automated database case definition for serious bleeding related to oral anticoagulant use
Andrew Cunningham et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Lars Wallentin et al.
LANCET (2010)
Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance
K. A. Kim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Elliott M. Antman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
